JERSEY, Channel Islands, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Heino von Prondzynski to the Company's Board of Directors. Mr. von Prondzynski will also serve as the Company's Lead Independent Director. Mr. von Prondzynski brings strong executive management and diverse global experience from leadership positions held at several major multinational healthcare companies.
"I am delighted to announce the appointment of Heino as a Director of Quotient," commented Paul Cowan, Chairman and Chief Executive Officer of Quotient. "He has had a highly distinguished career in the healthcare industry, delivering global growth and profitable expansion. With over 35 years experience in the field of pharmaceuticals, vaccines and medical diagnostics, Heino has shown a keen interest in talent development and a passion for driving product innovation."
Mr. von Prondzynski, 64, served as Chief Executive Officer of Roche Diagnostics and as a member of the Executive Committee of F. Hoffman-La Roche Ltd. from early 2000 to 2006, retiring from Roche at the end of 2006. While at Roche, he brought Roche Diagnostics, which included diabetes, near-patient testing, centralized diagnostics and applied science to global market leadership and record profitability. He also drove significant growth through an expansion of Roche's molecular diagnostics portfolio and entry into the donor-screening market. From 1996 to 2000, Mr. von Prondzynski held several executive positions, including President of the vaccine business at Chiron Corporation, a multinational firm developing biopharmaceuticals, vaccines and blood-testing products. Earlier in his career, Mr. von Prondzynski held sales and marketing and general management positions at Bayer A.G.
Mr. von Prondzynski currently serves on a number of public company boards of directors, including Royal Philips (Netherlands), Hospira Inc. (U.S.A.) and Epigenomics AG (Germany).
About Quotient Limited
Quotient Limited ("Quotient") is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests, currently focused on blood grouping and serological disease screening. Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins, Switzerland.
CONTACT: Paul Cowan, Chairman & Chief Executive Officer firstname.lastname@example.org; +41 79 128 6908Source:Quotient Biodiagnostics, Inc.